利伐沙班和达比加群酯在高龄非瓣膜性房颤患者中的 有效性及安全性观察

Objective: To investigate the efficacy and safety of Rivaroxaban and Dabigatran in elderly patients with non-valvular AF. Methods: A retrospective analysis of 202 elderly patients(Rivaroxaban = 116, Dabigatran = 86) with non-valvular atrial fibrillation hospitalized in our department of Cardiology from September 2016 to March 2018 was performed. The average follow-up period was 9 months. Comparation of the basic clinical data, the efficacy end point and clinical relevant bleeding between the two groups were done.Results: The efficacy end point occurred in 4 patients in the Rivaroxaban group and the Dabigatran group respectively. There was no significant difference in efficacy between the two groups(P > 0.05). Ischemic stroke was the most common thromboembolic events(4/8).Clinical relevant bleeding occurred in 15 patients in the Rivaroxaban group and 10 in the Dabigatran group. There was no significant difference in safety between the two groups(P > 0.05). Gastrointestinal bleeding was the most common bleeding events(7/25).Conclusions: The efficacy and safety of Rivaroxaban and Dabigartran in elderly patients with non-valvular AF are similar. [ABSTRACT FROM AUTHOR]